Multivariate eQTL mapping uncovers functional variation on the X-chromosome associated with complex disease traits
Ben M Brumpton1,2, Manuel A R Ferreira3
1Department of Public Health and General Practice, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Postbox 8905, MTFS, NO-7491, Trondheim, Norway. ben.brumpton@ntnu.no.
Human Genetics
|May 9, 2016
Summary
Researchers identified 548 X-chromosome expression SNPs (eSNPs) linked to gene expression variation. Some eSNPs associate with diseases, offering insights into genetic links to human traits and conditions.
Area of Science:
- Genomics
- Human Genetics
- Molecular Biology
Background:
- Investigating genetic polymorphisms and X-chromosome gene expression is crucial for understanding trait-associated variants found in genome-wide association studies (GWAS).
- Functional follow-up studies are often limited by a lack of knowledge regarding X-chromosome genetic associations.
Purpose of the Study:
- To identify single nucleotide polymorphisms (SNPs) associated with gene expression variation on the X-chromosome (eSNPs).
- To explore the link between identified eSNPs and known disease or trait-associated variants.
Main Methods:
- Utilized a multivariate approach to analyze associations between SNPs and exon expression levels.
- Examined data from 356 Epstein-Barr virus-transformed lymphoblastoid cell lines (LCLs) from the Geuvadis RNA sequencing project.
- Identified eSNPs on the X-chromosome using a false discovery rate (FDR) of 5% and linkage disequilibrium (LD) thresholds.
Main Results:
- Discovered 548 independent X-chromosome eSNPs.
- Found 35 eSNPs in high LD (r² > 0.8) with previously identified GWAS variants.
- Identified a strong eSNP (rs35975601) associated with F8A1 expression, in LD with a type 1 diabetes risk variant.
- Observed eSNPs for DNASE1L1 in LD with variants linked to bilirubin levels, type 1 diabetes, and schizophrenia.
Conclusions:
- Multivariate exon-level analysis is more powerful than univariate gene-level analysis for detecting expression quantitative trait loci (eQTLs).
- The identified X-chromosome eSNPs provide potential molecular mechanisms linking gene expression to human trait variation and disease risk.
- These findings enhance our understanding of X-chromosome genetic architecture and its role in complex traits.
More Related Videos
Related Concept Videos
X-linked Traits
59.4K
In most mammalian species, females have two X sex chromosomes and males have an X and Y. As a result, mutations on the X chromosome in females may be masked by the presence of a normal allele on the second X. In contrast, a mutation on the X chromosome in males more often causes observable biological defects, as there is no normal X to compensate. Trait variations arising from mutations on the X chromosome are called “X-linked”.
59.4K
X-linked Traits
7.9K
7.9K
Genome-wide Association Studies-GWAS
16.5K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
16.5K
Multiple Allele Traits
14.9K
14.9K
Multiple Allele Traits
38.6K
The Concept of Multiple Allelism
38.6K
Pharmacogenomics: Identification of New Drug Targets
75
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
75


